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Background: The widespread use of natural health products is also a problem, as they could interact with
prescribed drugs in patients. One commonly used product is glucosamine for osteoarthritis and some reports have
found increased values of cholesterol and other lipids in patients treated with simvastatin for hypercholesterolemia.
The aim of this trial was to investigate the effects of glucosamine on s-cholesterol levels (total s-cholesterol, s-HDL,
s-LDL) in primary care patients on treatment with simvastatin or atorvastatin.
Methods: Controlled, randomized, open, crossover pharmacodynamic study in two primary health care centres.
Patients were treated with ArtroxW (glucosamine) 625 mg twice daily and control (a commercially available
multivitamin tablet VitamineralW). The study started with a run-in period of four weeks followed by control or active
treatment with randomization of sealed envelopes. Each treatment period was four weeks and the treatment with
simvastatin or atorvastatin was unchanged during the study (12 weeks). 34 patients were treated with a stable dose
of simvastatin (n=21) or atorvastatin (n=13) for at least three months. Assessments of total s-cholesterol, s-HDL,
S-LDL and s-triglycerides were performed in the morning with the patients in a fasting condition. T-tests for paired
samples were used for statistical analyses and a p-value <0.05 was considered significant. Endpoints were the
differences in lipid values at week 8 and week 12.
Results: All patients completed the study. No significant changes were seen on any of lipid levels in the
simvastatin group.
Conclusion: The actual glucosamine product did not change lipid levels of patients treated with simvastatin.
Atorvastatin group was too small for safe calculations but was also without changes.
Trial registration: EUDRACT2006-001458-28Background
There is a widespread use of natural health products
[1,2]. It is also known that some of these products can
interact with several prescribed drugs [3], causing
increased levels for example of cholesterol and other
lipids [4,5] when interacting with the metabolism of
simvastatin and atorvastatin [4,5]. One drug that is
commonly used of patients suffering from osteoarthritis* Correspondence: robert.eggertsen@vgregion.se
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reproduction in any medium, provided the oris glucosamine, which is found naturally in the body
and also is used by the body as one of the building
blocks of cartilage. Some case reports have found
increased values of cholesterol and other lipids in
patients treated with simvastatin and glucosamine [6]
but no prospective studies have been conducted to
confirm these data. One long-term study of glucosa-
mine effects on osteoarthritis found no effects on lipids
but this was not made on patients treated with simvas-
tatin [7]. One Danish trial found similar results but
these patients were not either treated for hypercholes-
terolemia [8]. We have found effects on patientsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 patients characteristics
Simvastatin treatment n = 21
Mean
Dose mg 10-40 21
Age years 57-77 66
Male n 11
Female n 10
Weight kg 47-110 83
Length cm 157-185 169
Hypertension n 14
Diabetes n 9
Heart disease/stroke n 5
Systolic blood pressure mm Hg 110-178 169
Diastolic blood pressure mm Hg 60-90 78
Heart rate b/min 46-80 62
Atorvastatin treatment n = 13
Mean
Dose mg 10-20 15
Age years 47-75 67
Male n 9
Female n 4
Weight kg 60-105 87
Length cm 162-181 170
Hypertension n 8
Diabetes n 5
Heart disease/stroke n 4
Systolic blood pressure mm Hg 109-165 142
Diastolic blood pressure mm Hg 64-100 82
Heart rate b/min 50-76 63
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Wort as a consequence of interaction of the CYP3A4
(4,5). In one trial on healthy subjects, glucosamine was
tested together with noskapin where no such effects
could be demonstrated for glucosamine [9]. ArtroxW is
a widely used commercially available product contain-
ing 750 mg glucosaminehydrochlorid that is equivalent
with 625 mg glucosamine. The recommended daily
dose is 625 mg given twice daily. Patients in primary
health care often ask their doctor of possibilities to
take natural remedies or over-the counter drugs to-
gether with prescribed medicines. It is therefore im-
portant to investigate possible interactions to prevent
negative effects and give right advice to the patients.
Simvastatin and atorvastatin are to a large extent meta-
bolized by cytocrom P450 3A4. The hypothesis for our
study was that glucosamine could interfere with this
major metabolic pathway causing a deterioration in
lipid control as was reported for three cases in Den-
mark (8). Against the background that no trial is car-
ried out on patients on treatment for high levels of
lipids, we decided to investigate the influence of the
commercially available glucosamine product ArtroxW
on relevant pharmacodynamic interactions in patients
with hypercholesterolemia, treated with simvastatin or
atorvastatin in a randomized, controlled crossover
study.
Methods
There were totally 21 patients with hypercholesterolemia
on treatment with a stable dose of simvastatin (10–40
mg once daily) and 13 patients with atorvastatin (10–20
mg daily) that were included in the study. The 11 males
and 10 females in the simvastatin group had a mean age
of 66 years, range 57–77 years. Fourteen patients had
hypertension, nine type 2 diabetes and five had suffered
from cardiac infarction or stroke (Table 1). In the ator-
vastatin group there were nine men and four women
with a mean age of 67 years, range 47–75 years. Eight
patients had hypertension, five had diabetes, and four
had earlier experienced heart infarction or stroke
(Table 1).
The study was approved by the Swedish Medical
Products Agency and the Regional Ethical Board in
Western Sweden.
The study was performed as a randomised, open,
cross-over study, where the approved glucosamine con-
taining product ArtroxW was compared with an inactive
control (a commercially available vitamin product
named VitamineralW). Patients were recruited from the
primary health care centres in Mölnlycke and Landvet-
ter in the Western region of Sweden. Eligible patients
on simvastatin or atorvastatin treatment were identified
by the routinely used data system at the primary healthcare centres. Patient characteristics are given in Table 1.
Patients were invited by an introductory letter which
included information about the study. The information
leaflet was approved by the regional ethical board and
it was sent home to eligible patients. Those who were
willing to participate signed an informed consent and
were included in the study. No record was made of
those patients who did not respond to the information
letter.
Exclusion criteria were; unstable angina pectoris, re-
cent myocardial infarction (within a year), recent stroke
(within a year), cardiac failure, HIV and dementia. There
have not been shown any significant interactions involv-
ing glucosamine except case reports to warfarin treated
patients. However, we excluded same drugs as in our
earlier trials with St John´s Wort as our hypothesis was
a stimulation of CYP3A4. Thus, treatment with birth
control pills, warfarin, theofylline, cyclosporine, amitryp-
tilin, nortriptilin, digoxin or sertraline was not allowed.
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the initial visit (week 0), the patients were informed
about the study, inclusion and exclusion criteria were
verified and a physical examination was performed. All
blood samples were obtained in the fasting condition
and analysed at the accredited central laboratory at
Sahlgrenska University Hospital in Gothenburg (total s-
cholesterol, s-HDL-cholesterol, s-LDL-cholesterol and
s-triglycerides). The laboratory was unaware of patient
treatment. Patients were then to return after 4 weeks
(week 4) and another physical examination was per-
formed and blood samples as described at week 0
above were collected. At this visit, the treating phys-
ician randomised (using sealed envelopes performed by
a person not involved with patients), the order of treat-
ment with active (ArtroxW) and control (VitamineralW).
Thus, 50% started with active treatment and the other
50% started with control treatment and all were
crossed- over to the other treatment modality after
another 4 weeks (week 8). We considered that the
treatment period o four weeks was adequate for pos-
sible glucosamine effects to vanish and thus no fur-
ther wash out period was mandatory. Assessment of
total s-cholesterol, s-HDL and s-LDL-cholesterol and
s-triglycerides were then performed at the end of each
treatment period (week 8 and 12). Compliance was
verified by pill counting at each visit. The patients
were on their regular dose of simvastatin or atorvasta-
tin and the dose of simvastatin and atorvastatin was
kept unchanged during the whole study period until
all patients completed the study. The mean dose of
simvastatin was 21 mg (range 10 mg – 40 mg) and of
atorvastatin 14.6 mg (range 10–20 mg).
Glucosamine could have an effect on glucose metabol-
ism as stated in the SPC of the product. In order toTable 2 Effects on lipid and glucose values
Vitamineral mean and SD
s-LDL mmol/L 2.27+0.61
s-HDL mmol/L 1.62+0.55






s-total cholesterol mmol/L 4.51+0.65
s-triglyceridesmmol/L 1.74+1.05
p-glucose mmol/L 7.39+2.08
HbA1c mmol/mol 5.20+1.13exclude negative effects on this variable, HbA1c was fol-
lowed as a safety measure,
Statistics
T- test for paired samples was used for statistical ana-
lyses and a p-value <0.05 was considered significant.
The primary efficacy endpoint was the difference in
LDL-cholesterol at week 8 and 12 between active
treatment and control. Secondary endpoints were the
corresponding difference in total cholesterol, HDL-
cholesterol and in triglycerides. The study was powered
to detect a difference of 0.48 mmol/L with a power of
81.2 % with a significance level of 0.05 (two sided) and
a standard deviation within the groups of 0.52. Power
calculations showed that participation of 20 subjects
would give statistical significance. Randomization pro-




Basal measurements were made after four weeks of run-
in. There were no significant effects on s-LDL, s-HDL,
total s-cholesterol, or s-triglycerides after four weeks
treatment with glucosamine. Neither were there any sig-
nificant changes of p-glucose and HbA1c Table 2.
Atorvastatin group
This group (n=13) was too small for safe calculations
but also in this group there were no effects on the differ-
ent lipids that could be demonstrated when compared
with run-in determinations and after four weeks of ac-
tive treatment. Values of p-glucose and HbA1c were also
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side effects were reported.
Discussion
The main finding in our study was that we could not
demonstrate any significant effect on total s-cholesterol,
s-LDL, S-HDL or s-triglycerides after treatment with the
glucosamine product ArtroxW on patients treated with
neither simvastatin nor atorvastatin for increased levels
of lipids. However, the atorvastatin group comprised of
13 patients why safe conclusions could not be drawn
from these patients. This is valuable knowledge as the
use of glucosamine is widespread and a considerable
amount of people is now also treated with lipid lowering
drugs.
Many patients are not aware of possibilities for inter-
action with increasing lipid values and different natural
health products that you can buy on the counter [4,5].
We have used one commercial product in our trial but
results may be similar with other glucosamine products
Also positive effects are described of natural health pro-
ducts as for pomegranate preparations where reductions
in LDL-cholesterol have been demonstrated [10,11].
Such products are as a rule not tested for influence on
different metabolic interactions, why it is important to
make investigations in that field. There are made meta-
analysis of the effects of glucosamine but reports of
interactions and effects of lipids are missing [12,13].
Reports of glucose rising and induction of insulin resist-
ance of glucosamine have been discussed but not been
confirmed in clinical studies [14]. The Swedish Medical
Products Agency (MPA) points out that interaction
studies are lacking and precaution is important even if
the risks of interactions is estimated as low [14]. In our
material we could not find any disturbances in the glu-
cose metabolism, however the active treatment period
was only four weeks.
A limitation in our study is that it was not double-
blind, why we cannot exclude carry-over effects in the
cross-over regimen. However, the half life for glucosa-
mine is about two hours why this seems unlikely in
treatment periods of four weeks. Furthermore, the study
was randomized, and assessment of the lipids was per-
formed by an accredited central laboratory, blinded to
the treatment regimen. We can not with used sample
sizes definitely exclude that there may be a type 2 error
because our study was dimensioned to detect differences
between the groups. Further studies with larger materials
could be necessary. The metabolism of glucosamine is
not known. This was an explanatory study to investigate
if there was a signal that could verify clinical observa-
tions of possible interactions. If a signal had been
detected further studies on possible mechanism had
been justified.Conclusions
We conclude that no increased levels of lipids were seen
in patients on lipid lowering drugs as simvastatin if
they simultaneously take glucosamine for articulation
problems.
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